Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Jin Bu Huan

This article was originally published in The Tan Sheet

Executive Summary

FDA issues April 15 "Talk Paper" describing the hazards of consuming Jin Bu Huan Anodyne Tablets, an herbal imported from Kwangsi, China. The agency noted that the product has been listed on an FDA import alert with "more than a dozen" other Chinese herbals "known to be harmful due to adulteration and inadequate labeling" and that Jin Bu Huan is currently subject to "automatic import detention by FDA." FDA's Office of Health Affairs recently sent a notification to field offices to be on the look-out for Jin Bu Huan ("The Tan Sheet" April 11, In Brief)

You may also be interested in...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts